Peer-reviewed veterinary case report
Trilostane lowers insulin needs in diabetic dogs
By McLauchlan, G et al.·Published in The Journal of small animal practice·2010·Glasgow University, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective evaluation of the effect of trilostane on insulin requirement and fructosamine concentration in eight diabetic dogs with hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of eight diabetic dogs with Cushing's disease (hyperadrenocorticism) were treated with a medication called trilostane to see how it affected their insulin needs and blood sugar levels. While some dogs had their insulin doses reduced after starting trilostane, others needed more insulin, and two dogs sadly passed away within 40 days of treatment. Overall, the results showed that trilostane didn't consistently lower insulin requirements or blood sugar levels in these dogs. More research is needed to better understand how trilostane affects diabetic dogs.
People also search for: diabetic dog treatment · Cushing's disease insulin needs · trilostane for dogs · dog blood sugar management
Abstract
OBJECTIVES: To describe the effect of trilostane on insulin requirements and serum fructosamine in dogs with diabetes mellitus (DM) and hyperadrenocorticism (HAC). METHODS: Observational retrospective study of eight dogs. RESULTS: Median fructosamine concentration at presentation was 401 μmol/L (range 244 to 554 μmol/L). Median insulin dose at presentation was 1·1 IU/kg/dose (0·4 to 2·1 IU/kg/dose) administered twice daily in five animals and once in three. Four dogs had their insulin dose prospectively reduced at the start of trilostane therapy. The HAC was controlled within 28 days in seven dogs. The remaining case was controlled by 17 weeks. Two dogs died within 40 days of starting trilostane. The median fructosamine concentration was 438 μmol/L (range 325 to 600 μmol/L) after stabilisation of the HAC. One case had a consistent reduction in serum fructosamine concentration over the first four months. The median insulin dose after stabilisation of HAC was 1·5 IU/kg dose (range 0·25 to 3·0 IU/kg/dose). Insulin requirements were reduced in two cases after treatment with trilostane. Four dogs required increased insulin doses. CLINICAL SIGNIFICANCE: Insulin requirements and fructosamine concentrations do not consistently reduce during trilostane treatment for HAC. Prospective studies are required to provide recommendations regarding reductions in insulin doses with trilostane treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21121919/